Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

Piotr Lewczuk; Johannes Kornhuber; Hugo Vanderstichele; Eugeen Vanmechelen; Hermann Esselmann; Mirko Bibl; Stefanie Wolf; Markus Otto; Udo Reulbach; Heike Kölsch; Frank Jessen; Johannes Schröder; Peter Schönknecht; Harald Hampel; Oliver Peters; Erik Weimer; Robert Perneczky; Holger Jahn; Christian Luckhaus; Ulrich Lamla; Tillmann Supprian; Juan Manuel Maler; Jens Wiltfang

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

Standard

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. / Lewczuk, Piotr; Kornhuber, Johannes; Vanderstichele, Hugo; Vanmechelen, Eugeen; Esselmann, Hermann; Bibl, Mirko; Wolf, Stefanie; Otto, Markus; Reulbach, Udo; Kölsch, Heike; Jessen, Frank; Schröder, Johannes; Schönknecht, Peter; Hampel, Harald; Peters, Oliver; Weimer, Erik; Perneczky, Robert; Jahn, Holger; Luckhaus, Christian; Lamla, Ulrich; Supprian, Tillmann; Maler, Juan Manuel; Wiltfang, Jens.

in: NEUROBIOL AGING, Jahrgang 29, Nr. 6, 6, 2008, S. 812-818.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lewczuk, P, Kornhuber, J, Vanderstichele, H, Vanmechelen, E, Esselmann, H, Bibl, M, Wolf, S, Otto, M, Reulbach, U, Kölsch, H, Jessen, F, Schröder, J, Schönknecht, P, Hampel, H, Peters, O, Weimer, E, Perneczky, R, Jahn, H, Luckhaus, C, Lamla, U, Supprian, T, Maler, JM & Wiltfang, J 2008, 'Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.', NEUROBIOL AGING, Jg. 29, Nr. 6, 6, S. 812-818. <http://www.ncbi.nlm.nih.gov/pubmed/17239996?dopt=Citation>

APA

Lewczuk, P., Kornhuber, J., Vanderstichele, H., Vanmechelen, E., Esselmann, H., Bibl, M., Wolf, S., Otto, M., Reulbach, U., Kölsch, H., Jessen, F., Schröder, J., Schönknecht, P., Hampel, H., Peters, O., Weimer, E., Perneczky, R., Jahn, H., Luckhaus, C., ... Wiltfang, J. (2008). Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. NEUROBIOL AGING, 29(6), 812-818. [6]. http://www.ncbi.nlm.nih.gov/pubmed/17239996?dopt=Citation

Vancouver

Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. NEUROBIOL AGING. 2008;29(6):812-818. 6.

Bibtex

@article{0ce119efc546482aa7a2db7f496f46fe,

title = "Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.",

abstract = "In this report we evaluated the clinical performance of APOE genotyping and three protein biomarkers (total tau, beta-amyloid(1-42), and tau phosphorylated at threonine 181) in a prospective multicenter study using the INNO-BIA AlzBio3 assay applied on Luminex platform. Concentration of biomarkers of Alzheimer's disease in cerebrospinal fluid (CSF) was measured with multiplexing technology (n=223), and compared to the results of ELISA assays in patients with early dementias or mild cognitive impairment (MCI) collected at 12 gerontopsychiatric university departments, and APOE genotyping was performed. Concentrations of Abeta(1-42) were statistically significantly lower in MCI-AD subjects compared to MCI-O, and significantly lower in D-AD patients compared to MCI-O. P-tau(181P) concentrations were significantly higher in MCI-AD patients compared to MCI-O, and significantly higher in D-AD patients compared to MCI-O. The total tau concentrations in MCI-AD patients were significantly higher compared to MCI-O, and higher in D-AD compared to MCI-O, moreover, the concentration of total tau was significantly higher in D-AD compared to MCI-AD patients. For the differential diagnosis between D-AD and D-O, the optimal cutoff concentration of Abeta(1-42) was 197.7 pg/mL, and that for P-tau(181P) was 47.9 pg/mL. These cutoff values were also applied to discriminate between MCI-AD and MCI-O subjects. Simultaneous measurement of the biomarkers significantly improves management of the samples and quality control of the assays' performance.",

author = "Piotr Lewczuk and Johannes Kornhuber and Hugo Vanderstichele and Eugeen Vanmechelen and Hermann Esselmann and Mirko Bibl and Stefanie Wolf and Markus Otto and Udo Reulbach and Heike K{\"o}lsch and Frank Jessen and Johannes Schr{\"o}der and Peter Sch{\"o}nknecht and Harald Hampel and Oliver Peters and Erik Weimer and Robert Perneczky and Holger Jahn and Christian Luckhaus and Ulrich Lamla and Tillmann Supprian and Maler, {Juan Manuel} and Jens Wiltfang",

year = "2008",

language = "Deutsch",

volume = "29",

pages = "812--818",

journal = "NEUROBIOL AGING",

issn = "0197-4580",

publisher = "Elsevier Inc.",

number = "6",

}

RIS

TY - JOUR

T1 - Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

AU - Lewczuk, Piotr

AU - Kornhuber, Johannes

AU - Vanderstichele, Hugo

AU - Vanmechelen, Eugeen

AU - Esselmann, Hermann

AU - Bibl, Mirko

AU - Wolf, Stefanie

AU - Otto, Markus

AU - Reulbach, Udo

AU - Kölsch, Heike

AU - Jessen, Frank

AU - Schröder, Johannes

AU - Schönknecht, Peter

AU - Hampel, Harald

AU - Peters, Oliver

AU - Weimer, Erik

AU - Perneczky, Robert

AU - Jahn, Holger

AU - Luckhaus, Christian

AU - Lamla, Ulrich

AU - Supprian, Tillmann

AU - Maler, Juan Manuel

AU - Wiltfang, Jens

PY - 2008

Y1 - 2008

N2 - In this report we evaluated the clinical performance of APOE genotyping and three protein biomarkers (total tau, beta-amyloid(1-42), and tau phosphorylated at threonine 181) in a prospective multicenter study using the INNO-BIA AlzBio3 assay applied on Luminex platform. Concentration of biomarkers of Alzheimer's disease in cerebrospinal fluid (CSF) was measured with multiplexing technology (n=223), and compared to the results of ELISA assays in patients with early dementias or mild cognitive impairment (MCI) collected at 12 gerontopsychiatric university departments, and APOE genotyping was performed. Concentrations of Abeta(1-42) were statistically significantly lower in MCI-AD subjects compared to MCI-O, and significantly lower in D-AD patients compared to MCI-O. P-tau(181P) concentrations were significantly higher in MCI-AD patients compared to MCI-O, and significantly higher in D-AD patients compared to MCI-O. The total tau concentrations in MCI-AD patients were significantly higher compared to MCI-O, and higher in D-AD compared to MCI-O, moreover, the concentration of total tau was significantly higher in D-AD compared to MCI-AD patients. For the differential diagnosis between D-AD and D-O, the optimal cutoff concentration of Abeta(1-42) was 197.7 pg/mL, and that for P-tau(181P) was 47.9 pg/mL. These cutoff values were also applied to discriminate between MCI-AD and MCI-O subjects. Simultaneous measurement of the biomarkers significantly improves management of the samples and quality control of the assays' performance.

AB - In this report we evaluated the clinical performance of APOE genotyping and three protein biomarkers (total tau, beta-amyloid(1-42), and tau phosphorylated at threonine 181) in a prospective multicenter study using the INNO-BIA AlzBio3 assay applied on Luminex platform. Concentration of biomarkers of Alzheimer's disease in cerebrospinal fluid (CSF) was measured with multiplexing technology (n=223), and compared to the results of ELISA assays in patients with early dementias or mild cognitive impairment (MCI) collected at 12 gerontopsychiatric university departments, and APOE genotyping was performed. Concentrations of Abeta(1-42) were statistically significantly lower in MCI-AD subjects compared to MCI-O, and significantly lower in D-AD patients compared to MCI-O. P-tau(181P) concentrations were significantly higher in MCI-AD patients compared to MCI-O, and significantly higher in D-AD patients compared to MCI-O. The total tau concentrations in MCI-AD patients were significantly higher compared to MCI-O, and higher in D-AD compared to MCI-O, moreover, the concentration of total tau was significantly higher in D-AD compared to MCI-AD patients. For the differential diagnosis between D-AD and D-O, the optimal cutoff concentration of Abeta(1-42) was 197.7 pg/mL, and that for P-tau(181P) was 47.9 pg/mL. These cutoff values were also applied to discriminate between MCI-AD and MCI-O subjects. Simultaneous measurement of the biomarkers significantly improves management of the samples and quality control of the assays' performance.

M3 - SCORING: Zeitschriftenaufsatz

VL - 29

SP - 812

EP - 818

JO - NEUROBIOL AGING

JF - NEUROBIOL AGING

SN - 0197-4580

IS - 6

M1 - 6

ER -